Objective: To observe the expression of oncogene c-Fos, cyclin D1 and cyclin dependent kinase 4 (CDK4) in breast cancer and para-cancerous tissues and their correlation with clinicopathological features, and to analyze the survival of breast cancer. Methods: Western blot (WB) and real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) were used to detect the expression level of c-Fos protein and mRNA content of c-Fos, Cyclin-D1 and CDK4 in 20 cases of breast cancer and para-cancerous tissues. Breast tumor-on-a-chip was purchased to do immunohistochemical (IHC) experiment to analyze the relationship between expression levels of c-Fos, Cyclin-D1 and CDK4 and the clinicopathological features and prognosis of breast cancer. Results: WB test showed that the expression level of c-Fos protein in breast cancer was significantly higher than that in para-cancerous tissues, and the difference was statistically significant(P＜0.05). RT-qPCR method showed that the mRNA content of c-Fos in breast cancer was higher than that in para-cancerous tissues, however, the difference was not statistically significant(P＞0.05). The mRNA contents of Cyclin-D1 and CDK4 in breast cancer were significantly higher than those in para-cancerous tissues(P＜0.05). IHC experiment showed that the expression levels of c-Fos, Cyclin-D1 and CDK4 in breast cancer tissues were significantly higher than those in para-cancerous tissues, and the differences were statistically significant (P＜0.05). The expression levels of the three proteins in cancer tissues were all positively correlated(r=0.320,r=0.486,r=0.514,P＜0.05). In breast cancer, the expression level of c-Fos was correlated to clinical stage(P＜0.05), the expression level of Cyclin-D1 was correlated to vascular invasion(P＜0.05), the expression level of CDK4 was related to lymph node metastasis(P＜0.05), and the high expression of the three proteins was the risk factor to the over survival of breast cancer patients. Conclusion: c-Fos, Cyclin-D1 and CDK4 are highly expressed in breast cancer, and there is a positive correlation among them, which indicates that they involved in the occurrence and development of breast cancer. Highly expressed c-Fos, Cyclin-D1 and CDK4 is positively correlated with clinicopathological features of breast cancer, which is a risk factor to the prognosis of patients with breast cancer.
HU Wenhui
,
JU Hongge
,
LI Feng
,
ZHANG Wei
,
MA Junbing
,
CHEN Peng
,
LI Yuanyuan
,
SUN Yang
. Expression and correlation analysis of c-Fos, Cyclin-D1 and CDK4 in breast cancer[J]. Journal of Baotou Medical College, 2023
, 39(9)
: 1
-7
.
DOI: 10.16833/j.cnki.jbmc.2023.09.001
[1] Ferlay J,Colombet M,Soerjomatatram I,et al.Cancer statistics for the year2020: an overview[J].Int J Cancer,2021,149(4): 778-789.
[2] Fu J,Cheng L,Wang Y,et al.The RNA-binding protein RBPMS1 represses AP-1 signaling and regulates breast cancer cell proliferation and migration[J].Biochim Biophys Acta,2015,1853(1): 1-13.
[3] 李洁仪,薛晓文.靶向AP-1信号通路的抗肿瘤天然产物及化学结构修饰[J].广东化工,2022,49(9): 69-72.
[4] Komoike Y,Akiyama F,Iino Y.Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors[J].Breast Cancer,2005,12: 104-111.
[5] 王准,封巍,刘冠,等.88例早期乳腺癌术后胸壁复发的多因素分析[J].实用肿瘤杂志,2006,21: 453-456.
[6] Nio Y,Iguchi C,Itakura M,et al.High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor like disorders[J].Anticancer Res,2009,29: 1607-1610.
[7] Piechaczyk M,Blanchard JM.c-fos proto-oncogene regulation and function[J].Crit Rev Oncol Hematol,1994,17(2): 93-131.
[8] Gazon H,Barbeau B,Mesnard J,et al.Hijacking of the AP-1 signaling pathway during development of ATL[J].Front Microbiol,2017,(8): 2686.
[9] 程瑞雪,冯德云,郑晖,等.乳腺癌组织中p-MAPK活化对c-Fos和c-jun的激活作用[J].湖南医科大学学报,2001(1): 10-12.
[10] 左文娜,朱虹,李立萍,等.喉癌组织中RECK,MMP-2及C-FOS的表达变化及与临床病理特征的关系[J].临床与病理杂志,2019,39(8): 1641-1647.
[11] Manios K,Tsiambas E,Stavrakis I,et al.c-Fos/c-Jun transcription factors in non-small cell lung carcinoma[J].J BUON,2020,25(5): 2141-2143.
[12] 王晶,姜辉,高雅晨,等.原癌基因c-Fos与肾脏疾病关系研究进展[J].中华实用诊断与治疗杂志,2019,33(12): 1236-1238.
[13] 谭玉靓,唐标.三阴性乳腺癌关键基因FOS和SPP1的生物信息学分析[J].中国免疫学杂志,2021,37(12): 1454-1460,1467.
[14] Li GD,Hu XL,Sun L,et al.C-Fos upregulates P-glycoprotein,contributing to the development of multidrug resistance in HEp-2 laryngeal cancer cells with VCR-induced resistance[J].Cell Mol Biol Lett,2018,23: 6.
[15] Wang QZ,Liu HC,Wang Q,et al.Involvement of c-Fos in cell proliferation,migration,and invasion in osteosarcoma cells accompanied by altered expression of Wnt2 and Fzd9[J].PLoS One,2017,12(6): e0180558.
[16] Dong C,Ye DX,Zhang WB,et al.Overexpression of c-Fos promotes cell invasion and migration via CD44 pathway in oral squamous cell carcinoma[J].J Oral Pathol Med,2015,44(5): 353-60.
[17] Babu RL,Naveen Kumar M,Patil RH,et al.Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun,c-Fos,and Fra-1 in cell cycle regulation[J].Mol Cell Biochem,2013,380(1-2): 143-151.
[18] 疏楠,李连宏,孙志刚,等. P16、CDK4、cyclinD1在乳腺癌中的表达及临床意义[J].大连医科大学学报,2009,31(4): 255-259.
[19] 吕红兵,金岩,刘源,等. cyclin D1和CDK4蛋白在良性和恶性多形性腺瘤中的表达及定量分析[J].实用口腔医学杂志,2008,(4): 600-602
[20] 历春,何程远,赵颖,等. 非小细胞肺癌FOXP3与P53突变的关联及其对Cyclin D1和CDK4的表达调控作用[J].北华大学学报(自然科学版),2022,23(6): 780-784.
[21] Qiu ZH,Zhang WW,Zhang HH,et al. Brucea javanica oil emulsion improves the effect of radiotherapy on esophageal cancer cells by inhibiting cyclin D1-CDK4/6 axis[J].World J Gastroenterol,2019,25(20): 2463-2472.
[22] Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis[J].Eur J Cancer,2005,41(16): 2449-2461.
[23] To B,Isaac D,Andrechek ER. Studying lymphatic metastasis in breast cancer: current models,strategies,and clinical perspectives[J].Mammary Gland Biol Neoplasia,2020,25(3): 191-203
[24] Zouzoulas D,Tsolakidis D,Gitas G,et al. Breast cancer in women younger than 35 years old[J].Arch Gynecol Obstet,2020,302(3): 721-730
[25] Walsh SM,Zabor EC,Flynn J,et al. Breast cancer in young black women[J].Br J Surg,2020,107(6): 677-686.
[26] 曾洲红,朱秀梅,罗卫,等.应用β-catenin抗体检测脉管内癌栓可行性与乳腺癌预后相关性研究[J].当代医学,2012,18(8): 20-21.
